^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CDX-014

    i
    Other names: CDX-014
    Company:
    Celldex
    Drug class:
    Microtubule inhibitor, TIM-1-targeted antibody-drug conjugate
    Related drugs:
    almost4years
    Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. (PubMed, Invest New Drugs)
    Overall, CDX-014 exhibited a manageable toxicity profile and early signs of activity, supporting further evaluation of antibody-drug conjugates in patients with advanced RCC and potentially other TIM-1 expressing cancers. Trial registrationhttps://clinicaltrials.gov/ct2/show/NCT02837991 NCT02837991; July 20, 2016.
    Clinical • Journal
    |
    MUC1 (Mucin 1) • KIM1 (Kidney injury molecule 1)
    |
    CDX-014